Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (115)	11/18/2002 10:44:23 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

MDCO Had a good up-gap today after it had released yesterday the data from REPLACE II, its study of Angiomax on 6,000-patients. The results were released on the opening day of the meeting of the AHA in Chicago. The company said that "all primary and secondary endpoints of the study were met". Angiomax was found to be equally effective as the heparin-IIb/IIIa inhibitor combination, and patients given Angiomax had significantly fewer bleeding complications. Angiomax is expected to have sales around $36 M in 2002 and some analysts are considering that the drug's sales could double or possibly triple in 2003.<g> The stock was up 25.98% on volume of 5,905,146 ( about 17.3x its daily average) siliconinvestor.com The stock made today a new 52 wks H as it closed above its November 15 intra-day H.It has now to deal with the August 3,2001 H at 17.20 before it could test the late September 2001 double top at 20.02 and then the early September 2001 double top at 22.20.<g> siliconinvestor.com Bernard